Level C· Early human research exploring benefitsProspective StudyPubMed

Human inferior turbinate: an alternative tissue source of multipotent mesenchymal stromal cells.

Hwang SH., Kim SY., Park SH., Choi MY., Kang HW., Seol YJ.

Prospective Study with a reported sample of 10 on Scar, published in Otolaryngol Head Neck Surg (2012) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Otolaryngol Head Neck Surg (2012)
Country
England
Reported sample size
10
Source database
PubMed
PMID
22588732
DOI
10.1177/0194599812447172

Abstract (original English)

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells in adult tissues. Current challenges for the clinical application of MSCs include donor site morbidity, which underscores the need to identify alternative sources of MSCs. This study aimed to explore potential new sources of multipotent MSCs for use in tissue regeneration and the functional restoration of organs. Mixed methods research. Tertiary care center. The authors isolated MSCs from human inferior turbinate tissues discarded during turbinate surgery of 10 patients for nasal obstruction. The expression of surface markers for MSCs was assessed by fluorescence-activated cell sorting. The differentiation potential of human turbinate mesenchymal stromal cells (hTMSCs) was analyzed by immunohistochemistry, reverse transcriptase-polymerase chain reaction, and Western blot analysis. Surface epitope analysis revealed that hTMSCs were negative for CD14, CD19, CD34, and HLA-DR and positive for CD29, CD73, and CD90, representing a characteristic phenotype of MSCs. Extracellular matrices with characteristics of cartilage, bone, and adipose tissue were produced by inducing the chondrogenic, osteogenic, and adipogenic differentiation of hTMSCs, respectively. The expression of neuron-specific markers in hTMSCs was confirmed immunocytochemically. The hTMSCs represent a new source of multipotent MSCs that are potentially app

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Blotting, WesternCell DifferentiationFlow CytometryHumansMesenchymal Stem CellsMultipotent Stem CellsReverse Transcriptase Polymerase Chain ReactionTissue EngineeringTurbinates

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research